Below, we illustrate this approach in settings where we have prior knowledge of which signatures are present in each sample: chemotherapy-related signatures in MM and acute myeloid leukemia (AML), and nc-AID activity in chronic lymphocytic leukemia (CLL). This evidence concerns the gene AICDA and Miyoshi myopathy.